Developer docs
API playgroundTry for free, no card

Search company profiles

Spectral AI

Full company profile

uuid00006hq

Namestring
Spectral AI
Legal namestring
Spectral AI, Inc.
Websiteurl
spectral-ai.com
Company typeenum
Public
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI wound diagnostics, multispectral imaging devices, burn wound assessment, predictive wound healing, medical imaging AI
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Wound Care Diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Government R&D Contract Revenue (BARDA / DoD)
TypeProfessional Services
Description

Primary current revenue stream from non-dilutive U.S. government research contracts including BARDA Project BioShield contract valued up to $150M (with $54.9M committed plus additional $31.7M advanced funding and company co-investment of $9.7M); also includes Defense Health Agency and Department of Defense contracts. R&D revenue was $4.0M in Q1 2026 versus $6.7M in Q1 2025, declining as base BARDA phase concluded.

globenewswire.com
2DeepView System Hardware Sales (Planned Commercial Launch)
TypeHardware Sales
Description

Anticipated commercial sales of the DeepView System to U.S. hospitals/burn centers following FDA De Novo Classification in May 2026; expected first commercial sales by year-end 2026 with 2026 revenue guidance of approximately $18.5 million.

stocktitan.net
3Equity & Debt Capital Raises
TypeLicensing Royalties
Description

Funding from public/private placement ($7.6M offering in October 2025) and debt financing (up to $15M from Avenue Venture Opportunities Fund II) used to support commercialization and product development.

marketscreener.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Quote-based / not publicly disclosed; device sold by or on the order of a physician
ModelOther
Notes

2026 annual revenue guidance of approximately $18.5 million disclosed; no per-unit or subscription price publicly listed on company website.

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DeepView
Description

AI-powered wound assessment and imaging platform combining multispectral imaging with proprietary AI algorithms to predict wound healing potential for burn wounds and diabetic foot ulcers.

spectral-ai.com
+1 more record
Core offering1 text field

Spectral AI develops and sells the DeepView AI System, a medical device that combines proprietary multispectral imaging (8 wavelengths across 400-900 nm) with proprietary AI algorithms trained on a 340+ billion data point burn wound database to deliver objective, Day-One binary predictions of wound healing potential. The system is FDA De Novo cleared for burn wound assessment (May 2026), UKCA authorized (February 2024), and supported by the portable DeepView SnapShot imaging platform; primary customers are hospitals, burn centers, NHS trusts, and U.S. government agencies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 92% accuracy on Day One in predicting if a burn wound will heal or not
+5 more records
Product overview1 text field

Spectral AI's offering centers on the DeepView AI® System, a single unified AI-powered predictive wound imaging platform that combines proprietary multispectral imaging hardware with deep learning algorithms to deliver Day-One wound healing predictions. The platform is delivered through the DeepView SnapShot® Imaging Platform (the portable hardware backbone) and is configured for multiple clinical indications through branded variants, including DeepView AI®-Burn (the FDA De Novo cleared thermal burn wound assessment device in the US and UKCA-marked device in the UK) and the DFU application for diabetic foot ulcers. The technology stack integrates 8-wavelength multispectral imaging (400-900nm), proprietary AI algorithms trained on over 340 billion data points from the world's largest burn biopsy tissue database, and optional EHR connectivity, delivering a binary healing prediction (healing vs non-healing) in approximately 20-25 seconds following a 0.2-second image acquisition. Spectral AI also maintains a clinical application pipeline exploring additional indications such as venous leg ulcer, critical limb ischemia, AI-guided therapy, AI-3D wound measurement, AI-digital health, and AI-cosmetics.

Product and service2 records
1DeepView AI System
CategoryAI diagnostic platform
Description

An AI-based wound assessment and imaging platform that combines proprietary multispectral imaging with deep learning to deliver objective, Day-One binary predictions of wound healing potential for clinicians. FDA De Novo cleared for the burn indication in May 2026 and UKCA marked since February 2024; image acquisition takes 0.2 seconds and AI classification output is delivered in approximately 20-25 seconds. Achieved 92% accuracy in predicting burn wound healing potential compared with 50-70% clinician visual assessment. Sold by or on the order of a physician.

2DeepView SnapShot Imaging Platform
CategoryHardware imaging platform
Description

A universal, portable hardware imaging platform that powers the DeepView AI System across multiple clinical indications and healthcare settings. Features multispectral camera capture with 8 unique wavelengths (400-900 nm), point-of-care bedside operation, rapid 0.2-second non-contact image acquisition, optional EHR connectivity, and supports burn, DFU, VLU, CLI, and AI-guided therapy indications.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1American Board of Wound Management Foundation
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-01
Description

Co-marketing / awareness partner during the 10th Annual Wound Healing Awareness Month in June 2026; joint campaign highlighting FDA De Novo Classification of the DeepView System for burn wound assessment.

stocktitan.net
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-02-01
Description

Joint participation in National Burn Awareness Week 2026 (Feb 1-7, 2026), emphasizing burn prevention in workplaces; Spectral AI has been a regular participant at ABA Annual Meetings (e.g., 2026 Orlando meeting).

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-04-30
Description

Annual conference partner; Spectral AI participated in the 2025 BBA Annual Meeting (UK hospitals presented DeepView findings) and the 2026 BBA Annual Conference (June 17-19, 2026, Nottingham Trent University), where Dr. Jeffrey Carter won first prize for presentation on multispectral imaging with AI for burn wounds.

4Children's Burns Trust (CBT)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Spectral AI is a 'Proud Sponsor' of Children's Burns Trust in the UK, supporting burn prevention campaigns such as National Burn Awareness Day and Child Safety Week and helping reduce burn injuries to children.

spectral-ai.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MolecuLight develops handheld point-of-care wound imaging devices using fluorescence to detect bacterial load and wound characteristics, targeting burn centers, wound clinics, and hospitals. Directly comparable to Spectral AI in terms of handheld form factor, point-of-care wound assessment, and burn/wound clinician customer base.

TypeDirect peer
Description

Swift Medical (now Swift) provides AI-powered smartphone wound measurement and imaging software widely used in wound care clinics and home health. Highly comparable as an AI-driven wound imaging platform serving similar clinical customers with similar predictive/measurement use cases.

TypeDirect peer
Description

Tissue Analytics, now part of Net Health, provides AI-enabled smartphone wound imaging and documentation used across hospital wound care and post-acute settings. Directly comparable in AI wound imaging, EHR integration, and burn/DFU workflows.

TypeDirect peer
Description

ARANZ Medical's Silhouette system provides 3D wound measurement and documentation for wound care and clinical research. Comparable in wound imaging hardware and clinical decision support for wound healing assessment.

TypeDirect peer
Description

eKare offers 3D wound imaging and AI-based wound measurement for hospitals, research, and clinical trials. Comparable AI-powered wound imaging platform serving similar clinical workflows in burn and chronic wound care.

TypeBroad incumbent
Description

HeartFlow is a commercial-stage medical imaging AI SaMD company providing non-invasive coronary disease assessment. Comparable as a clinically validated, FDA-cleared AI imaging SaMD with a similar enterprise sales motion into hospitals and specialist clinicians.

TypeBroad incumbent
Description

Aidoc is a broad medical imaging AI platform with multiple FDA-cleared algorithms for radiology triage and notification. Comparable in AI medical imaging SaMD model, hospital enterprise sales motion, and clinical decision support positioning.

TypeBroad incumbent
Description

Viz.ai develops AI-powered imaging software for time-sensitive conditions (e.g., stroke triage), with an FDA-cleared SaMD model sold into hospitals. Comparable as a specialized clinical imaging AI SaMD with an enterprise hospital sales motion.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device company with a large Advanced Wound Management portfolio. Comparable as a broad incumbent in wound care addressing burn and chronic wound customers, providing context for market scale and competitive intensity.

TypeBroad incumbent
Description

Mölnlycke is a major wound care and surgical solutions company with significant global presence in burn and chronic wound management. Comparable as a broad incumbent in the wound care ecosystem serving similar clinician customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spectral AI

AI Wound Care Diagnosticsspectral-ai.com

Spectral AI firmographics

Firmographics
Name
Spectral AI
Legal name
Spectral AI, Inc.
Website
https://spectral-ai.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Spectral AI industry classification

Industry
Product category
AI Wound Care Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • AI wound diagnostics
  • Multispectral imaging devices
  • Burn wound assessment
  • Predictive wound healing
  • Medical imaging AI

Where Spectral AI is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Spectral AI business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Government R&D Contract Revenue (BARDA / DoD): Primary current revenue stream from non-dilutive U.S. government research contracts including BARDA Project BioShield contract valued up to $150M (with $54.9M committed plus additional $31.7M advanced funding and company co-investment of $9.7M); also includes Defense Health Agency and Department of Defense contracts. R&D revenue was $4.0M in Q1 2026 versus $6.7M in Q1 2025, declining as base BARDA phase concluded.
  2. DeepView System Hardware Sales (Planned Commercial Launch): Anticipated commercial sales of the DeepView System to U.S. hospitals/burn centers following FDA De Novo Classification in May 2026; expected first commercial sales by year-end 2026 with 2026 revenue guidance of approximately $18.5 million.
  3. Equity & Debt Capital Raises: Funding from public/private placement ($7.6M offering in October 2025) and debt financing (up to $15M from Avenue Venture Opportunities Fund II) used to support commercialization and product development.

Pricing tiers

ModelBillingPrice
Other—Quote-based / not publicly disclosed; device sold by or on the order of a physician

Go-to-market motion4 records

Distribution channels4 records

Marketing channels10 records

Spectral AI product offering

Product offering

Core offering

Spectral AI develops and sells the DeepView AI System, a medical device that combines proprietary multispectral imaging (8 wavelengths across 400-900 nm) with proprietary AI algorithms trained on a 340+ billion data point burn wound database to deliver objective, Day-One binary predictions of wound healing potential. The system is FDA De Novo cleared for burn wound assessment (May 2026), UKCA authorized (February 2024), and supported by the portable DeepView SnapShot imaging platform; primary customers are hospitals, burn centers, NHS trusts, and U.S. government agencies.

Product overview

Spectral AI's offering centers on the DeepView AI® System, a single unified AI-powered predictive wound imaging platform that combines proprietary multispectral imaging hardware with deep learning algorithms to deliver Day-One wound healing predictions. The platform is delivered through the DeepView SnapShot® Imaging Platform (the portable hardware backbone) and is configured for multiple clinical indications through branded variants, including DeepView AI®-Burn (the FDA De Novo cleared thermal burn wound assessment device in the US and UKCA-marked device in the UK) and the DFU application for diabetic foot ulcers. The technology stack integrates 8-wavelength multispectral imaging (400-900nm), proprietary AI algorithms trained on over 340 billion data points from the world's largest burn biopsy tissue database, and optional EHR connectivity, delivering a binary healing prediction (healing vs non-healing) in approximately 20-25 seconds following a 0.2-second image acquisition. Spectral AI also maintains a clinical application pipeline exploring additional indications such as venous leg ulcer, critical limb ischemia, AI-guided therapy, AI-3D wound measurement, AI-digital health, and AI-cosmetics.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepView: AI-powered wound assessment and imaging platform combining multispectral imaging with proprietary AI algorithms to predict wound healing potential for burn wounds and diabetic foot ulcers.
  • DeepView SnapShot

Products and services

  • DeepView AI System An AI-based wound assessment and imaging platform that combines proprietary multispectral imaging with deep learning to deliver objective, Day-One binary predictions of wound healing potential for clinicians. FDA De Novo cleared for the burn indication in May 2026 and UKCA marked since February 2024; image acquisition takes 0.2 seconds and AI classification output is delivered in approximately 20-25 seconds. Achieved 92% accuracy in predicting burn wound healing potential compared with 50-70% clinician visual assessment. Sold by or on the order of a physician.
  • DeepView SnapShot Imaging Platform A universal, portable hardware imaging platform that powers the DeepView AI System across multiple clinical indications and healthcare settings. Features multispectral camera capture with 8 unique wavelengths (400-900 nm), point-of-care bedside operation, rapid 0.2-second non-contact image acquisition, optional EHR connectivity, and supports burn, DFU, VLU, CLI, and AI-guided therapy indications.

Quantifiable outcome

  • 92% accuracy on Day One in predicting if a burn wound will heal or not
  • +5 more outcomes

Companies that use Spectral AI

Customer profile

Named customers5 records

Ideal customer profiles3 records

Spectral AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature7 records

Spectral AI partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • American Board of Wound Management FoundationminorGTM or Marketing Partner · 1 June 2026Co-marketing / awareness partner during the 10th Annual Wound Healing Awareness Month in June 2026; joint campaign highlighting FDA De Novo Classification of the DeepView System for burn wound assessment.
  • American Burn Association (ABA)minorGTM or Marketing Partner · 1 February 2026Joint participation in National Burn Awareness Week 2026 (Feb 1-7, 2026), emphasizing burn prevention in workplaces; Spectral AI has been a regular participant at ABA Annual Meetings (e.g., 2026 Orlando meeting).
  • British Burn Association (BBA)coreGTM or Marketing Partner · 30 April 2025Annual conference partner; Spectral AI participated in the 2025 BBA Annual Meeting (UK hospitals presented DeepView findings) and the 2026 BBA Annual Conference (June 17-19, 2026, Nottingham Trent University), where Dr. Jeffrey Carter won first prize for presentation on multispectral imaging with AI for burn wounds.
  • Children's Burns Trust (CBT)minorGTM or Marketing Partner · 1 January 2024Spectral AI is a 'Proud Sponsor' of Children's Burns Trust in the UK, supporting burn prevention campaigns such as National Burn Awareness Day and Child Safety Week and helping reduce burn injuries to children.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Spectral AI competitors and assessment

Company assessment

Direct peers

  • MolecuLight: MolecuLight develops handheld point-of-care wound imaging devices using fluorescence to detect bacterial load and wound characteristics, targeting burn centers, wound clinics, and hospitals. Directly comparable to Spectral AI in terms of handheld form factor, point-of-care wound assessment, and burn/wound clinician customer base.
  • Swift Medical: Swift Medical (now Swift) provides AI-powered smartphone wound measurement and imaging software widely used in wound care clinics and home health. Highly comparable as an AI-driven wound imaging platform serving similar clinical customers with similar predictive/measurement use cases.
  • Tissue Analytics (a Net Health company): Tissue Analytics, now part of Net Health, provides AI-enabled smartphone wound imaging and documentation used across hospital wound care and post-acute settings. Directly comparable in AI wound imaging, EHR integration, and burn/DFU workflows.
  • ARANZ Medical: ARANZ Medical's Silhouette system provides 3D wound measurement and documentation for wound care and clinical research. Comparable in wound imaging hardware and clinical decision support for wound healing assessment.
  • eKare: eKare offers 3D wound imaging and AI-based wound measurement for hospitals, research, and clinical trials. Comparable AI-powered wound imaging platform serving similar clinical workflows in burn and chronic wound care.

Broad incumbents

  • HeartFlow: HeartFlow is a commercial-stage medical imaging AI SaMD company providing non-invasive coronary disease assessment. Comparable as a clinically validated, FDA-cleared AI imaging SaMD with a similar enterprise sales motion into hospitals and specialist clinicians.
  • Aidoc: Aidoc is a broad medical imaging AI platform with multiple FDA-cleared algorithms for radiology triage and notification. Comparable in AI medical imaging SaMD model, hospital enterprise sales motion, and clinical decision support positioning.
  • Viz.ai: Viz.ai develops AI-powered imaging software for time-sensitive conditions (e.g., stroke triage), with an FDA-cleared SaMD model sold into hospitals. Comparable as a specialized clinical imaging AI SaMD with an enterprise hospital sales motion.
  • Smith+Nephew: Smith+Nephew is a global medical device company with a large Advanced Wound Management portfolio. Comparable as a broad incumbent in wound care addressing burn and chronic wound customers, providing context for market scale and competitive intensity.
  • Mölnlycke Health Care: Mölnlycke is a major wound care and surgical solutions company with significant global presence in burn and chronic wound management. Comparable as a broad incumbent in the wound care ecosystem serving similar clinician customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Spectral AI social profiles

Digital presence

Spectral AI compliance and trust

Trust signal

Compliance2 records

Spectral AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spectral AI leadership team

Management profile

Number of profiles

Profiles8 records

Spectral AI subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Spectral AI funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spectral AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectral AI

What does Spectral AI do?

Spectral AI develops and sells the DeepView AI System, a medical device that combines proprietary multispectral imaging (8 wavelengths across 400-900 nm) with proprietary AI algorithms trained on a 340+ billion data point burn wound database to deliver objective, Day-One binary predictions of wound healing potential. The system is FDA De Novo cleared for burn wound assessment (May 2026), UKCA authorized (February 2024), and supported by the portable DeepView SnapShot imaging platform; primary customers are hospitals, burn centers, NHS trusts, and U.S. government agencies.

Is Spectral AI a public or private company?

Spectral AI is a public company. It is classified as public and is currently operating.

When was Spectral AI founded?

Spectral AI was founded in 2013. It employs 51 to 100 people.

Where is Spectral AI based?

Spectral AI is headquartered in Dallas, United States, in the North America region.

How does Spectral AI make money?

Three revenue lines are on record. Government R&D Contract Revenue (BARDA / DoD) is the primary driver. The others are deepView System Hardware Sales (Planned Commercial Launch) and equity & Debt Capital Raises.

Who are Spectral AI's main competitors?

Direct peers on record are MolecuLight, Swift Medical, Tissue Analytics (a Net Health company), ARANZ Medical and eKare. Broad incumbents are HeartFlow, Aidoc, Viz.ai, Smith+Nephew and Mölnlycke Health Care.

Does Spectral AI have an API?

No public API is recorded for Spectral AI.

What industry is Spectral AI in?

Spectral AI's product category is AI Wound Care Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEarnings call transcript: Spectral AI Q3 2026 revenue miss sends shares lowerSpectral AI reported Q3 2026 revenue of $2.86 million, missing the $5.33 million forecast, while posting an adjusted loss of $0.11 per share, beating the $0.13 estimate. Shares fell 14.93% after hours to $1.31, and management cut its 2026 R&D revenue guidance to about $13 million from $18.5 million.The future of tradingSpectral AI publishes update to financial calendarSpectral AI will report its third-quarter 2026 financial results on November 10, 2026, following the Nasdaq close. A conference call with a simultaneous webcast is scheduled for November 10 at 5 p.m. Eastern Time.Stock TitanSpectral AI showcased FDA-cleared burn system at ACEPSpectral AI showcased its FDA-cleared DeepView burn assessment system at the 2026 ACEP Scientific Assembly in Chicago. The system, granted De Novo classification in May 2026, provides a 0.2-second image acquisition and 20-25 second AI classification to assess burn wound healing potential. The company aims to integrate it into emergency care workflows.American Banking and Market NewsAnalyzing Spectral AI (NASDAQ:MDAI) and Hyperfine (NASDAQ:HYPR)Spectral AI and Hyperfine are compared on profitability, institutional ownership, and analyst ratings. Spectral AI beats Hyperfine on 9 of 15 factors, with higher revenue and a lower price-to-earnings ratio. Analysts favor Spectral AI, citing a higher consensus rating and greater upside.Markets DailyFinancial Analysis: Spectral AI (NASDAQ:MDAI) versus Hyperfine (NASDAQ:HYPR)Spectral AI beats Hyperfine on 9 of 15 factors, including higher revenue and lower P/E. Spectral AI has a stronger consensus rating and higher upside potential. Spectral AI is trading at a lower price-to-earnings ratio than Hyperfine.American Banking and Market NewsReviewing Teleflex (NYSE:TFX) and Spectral AI (NASDAQ:MDAI)Teleflex and Spectral AI are compared on profitability, analyst ratings, and valuation. Spectral AI has higher potential upside (140.96% vs 23.20%) but lower revenue and higher volatility. Teleflex trades at a lower P/E ratio, making it more affordable.The future of tradingSpectral AI launches DeepView clinical study to support FDA label expansion for head, hands and feet burnsSpectral AI launched a clinical study to support expanding the DeepView System's FDA-cleared burn label to head, hand, and foot burns. No clinical results have been presented; the trial is designed to generate evidence for a future label expansion submission. The first site initiation visit was completed at Pinderfields Hospital in the UK, enabling patient enrollment to begin.Stock TitanSpectral AI completes first burn-study site initiation visitSpectral AI completed the first site initiation visit for a clinical study of its DeepView System to support label expansion for burns of the head, hands, and feet. The study, led by Dr. Preetha Muthayya at Pinderfields Hospital, will enroll patients and is expected to be completed in 2027.Markets DailyAnalyzing Teleflex (NYSE:TFX) & Spectral AI (NASDAQ:MDAI)Spectral AI and Teleflex are compared on valuation, earnings, institutional ownership, and profitability. Spectral AI has a higher consensus rating and potential upside of 151.57% versus Teleflex's 24.88%, and it beats Teleflex on 8 of 15 factors. Teleflex trades at a lower price-to-earnings ratio but has lower profitability.BioSpaceSpectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn WoundsSpectral AI announced a presentation at ACS Clinical Congress 2026 in Washington, DC, led by Dr. James H. Holmes IV. The presentation highlights its FDA-cleared DeepView System, which uses multispectral imaging and AI to assess burn wound healing potential. The company aims to expand awareness beyond the burn specialty.